Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

PHASE3RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions
Glucose Intolerance After a Recent History of Gestational Diabetes
Interventions
DRUG

Semaglutide Pen Injector

maintenance dose of 1mg SC once weekly

DRUG

Semaglutide placebo

maintenance dose of 1mg SC once weekly

Trial Locations (13)

Unknown

RECRUITING

OLV-Aalst-Asse, Aalst

RECRUITING

UZA, Antwerp

RECRUITING

ZNA,, Antwerp

RECRUITING

AZ St Jan Brugge, Bruges

RECRUITING

Erasme, Brussels

RECRUITING

UZ Brussel, Brussels

RECRUITING

Jan Yperman, Ieper

RECRUITING

AZ Groeninge Kortrijk, Kortrijk

RECRUITING

UZ Leuven, Leuven

RECRUITING

CHU de Liège, Liège

RECRUITING

Centre Hospitalier Mouscron, Mouscron

RECRUITING

Vitaz, Sint-Niklaas

RECRUITING

AZ Turnhout, Turnhout

All Listed Sponsors
collaborator

University Hospital, Antwerp

OTHER

collaborator

Universitair Ziekenhuis Brussel

OTHER

collaborator

General Hospital Groeninge

OTHER

collaborator

Onze Lieve Vrouw Hospital

OTHER

collaborator

Jessa Hospital

OTHER

collaborator

Ziekenhuis Netwerk Antwerpen (ZNA)

OTHER

collaborator

Vitaz

OTHER

collaborator

Centre Hospitalier Universitaire de Liege

OTHER

collaborator

Erasme University Hospital

OTHER

collaborator

Centre Hospitalier Mouscron

UNKNOWN

collaborator

Jan Yperman Ziekenhuis

OTHER

collaborator

AZ Turnhout

OTHER

collaborator

AZ Sint-Lucas Brugge

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER